Skip to Main Content

Author Details

Eric A Collisson
University of California san francisco
1999
102
48
PMIDPaper TitleJournal TitlePublished Year
37577651Conserved regulatory motifs in the juxtamembrane domain and kinase N-lobe revealed through deep mutational scanning of the MET receptor tyrosine kinase domain.bioRxiv2024
38017076Author Correction: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.Nat Med2024
37296367RAS and Other Molecular Targets in Pancreatic Cancer: The Next Wave Is Coming.Curr Treat Options Oncol2023
37505926A Genomic Analysis of Esophageal Squamous Cell Carcinoma in Eastern Africa.Cancer Epidemiol Biomarkers Prev2023
37044094Development of an artificial intelligence-derived histologic signature associated with adjuvant gemcitabine treatment outcomes in pancreatic cancer.Cell Rep Med2023
34627860Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma via Autophagy Inhibition, MEK Blockade, and CD40 Agonism.Gastroenterology2022
35675073Comparison of FOLFIRINOX vs Gemcitabine Plus Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma.JAMA Netw Open2022
35837755An international report on bacterial communities in esophageal squamous cell carcinoma.Int J Cancer2022
35834226Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas: The A021501 Phase 2 Randomized Clinical Trial.JAMA Oncol2022
35695740The Additional Diagnostic Benefit of Pancreatic Cancer Molecular Profiling After Germline Testing.Pancreas2022
35858545Mutant KRAS regulates transposable element RNA and innate immunity via KRAB zinc-finger genes.Cell Rep2022
35262628Ferrous iron-activatable drug conjugate achieves potent MAPK blockade in KRAS-driven tumors.J Exp Med2022
33261861Ferrous Iron-Dependent Pharmacology.Trends Pharmacol Sci2021
33626341Whole-genome characterization of lung adenocarcinomas lacking alterations in the RTK/RAS/RAF pathway.Cell Rep2021
33860789State of the structure address on MET receptor activation by HGF.Biochem Soc Trans2021
34848876Author Correction: Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.Nature2021
34506673Implementation of an Embedded In-Clinic Genetic Testing Station to Optimize Germline Testing for Patients with Pancreatic Adenocarcinoma.Oncologist2021
34476331Retrospective Case Series Analysis of <i>RAF</i> Family Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies.JCO Precis Oncol2021
34009124Single-cell transcriptome analysis defines heterogeneity of the murine pancreatic ductal tree.Elife2021
31548343Co-occurring Alterations in the RAS-MAPK Pathway Limit Response to MET Inhibitor Treatment in MET Exon 14 Skipping Mutation-Positive Lung Cancer.Clin Cancer Res2020
33324741Metastatic Donor-derived Malignancies Following Simultaneous Pancreas-kidney Transplant: Three Case Reports and Management Strategies.Transplant Direct2020
33152701Molecular Insights in Transmission of Cancer From an Organ Donor to Four Transplant Recipients.J Natl Compr Canc Netw2020
32661068Distinctions with a Difference: RNA Subtyping and Clinical Outcome in Pancreatic Cancer.Clin Cancer Res2020
32699215Multi-faceted epigenetic dysregulation of gene expression promotes esophageal squamous cell carcinoma.Nat Commun2020
32755156Estimation of Fractional Extracellular Space at CT for Predicting Chemotherapy Response and Survival in Pancreatic Ductal Adenocarcinoma.AJR Am J Roentgenol2020
32749238Pancreatic ductal adenocarcinoma progression is restrained by stromal matrix.J Clin Invest2020
32341034Theranostic Targeting of CUB Domain Containing Protein 1 (CDCP1) in Pancreatic Cancer.Clin Cancer Res2020
32196460Blockchain-Authenticated Sharing of Genomic and Clinical Outcomes Data of Patients With Cancer: A Prospective Cohort Study.J Med Internet Res2020
30267352Referral frequency, attrition rate, and outcomes of germline testing in patients with pancreatic adenocarcinoma.Fam Cancer2019
31296870Blockade of leukemia inhibitory factor as a therapeutic approach to KRAS driven pancreatic cancer.Nat Commun2019
30996350Targeting LIF-mediated paracrine interaction for pancreatic cancer therapy and monitoring.Nature2019
30718832Molecular subtypes of pancreatic cancer.Nat Rev Gastroenterol Hepatol2019
29622700Hybrid Capture-Based Tumor Sequencing and Copy Number Analysis to Confirm Origin of Metachronous Metastases in <i>BRCA1-</i>Mutant Cholangiocarcinoma Harboring a Novel <i>YWHAZ-BRAF</i> Fusion.Oncologist2018
30135250APOBEC mutation drives early-onset squamous cell carcinomas in recessive dystrophic epidermolysis bullosa.Sci Transl Med2018
30181169Bringing Pancreas Cancer into the Lab.Cancer Discov2018
30063366Early Response Assessment in Pancreatic Ductal Adenocarcinoma Through Integrated PET/MRI.AJR Am J Roentgenol2018
30376975The Role of MR Imaging in Pancreatic Cancer.Magn Reson Imaging Clin N Am2018
30506016Stromal Content Is Correlated With Tissue Site, Contrast Retention, and Survival in Pancreatic Adenocarcinoma.JCO Precis Oncol2018
29760388Cell of origin and mutation pattern define three clinically distinct classes of sebaceous carcinoma.Nat Commun2018
28522754<i>MET</i> Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.Cancer Res2017
28292434Pancreatic Cancer Genomics 2.0: Profiling Metastases.Cancer Cell2017
28096419Stromal cues regulate the pancreatic cancer epigenome and metabolome.Proc Natl Acad Sci U S A2017
28209609Pancreatic Cancer: Progress and Challenges in a Rapidly Moving Field.Cancer Res2017
29228650Ultrasensitive plasma ctDNA <i>KRAS</i> assay for detection, prognosis, and assessment of therapeutic response in patients with unresectable pancreatic ductal adenocarcinoma.Oncotarget2017
29189326Advances in the Genetics and Biology of Pancreatic Cancer.Cancer J2017
29020035Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer.PLoS One2017
28750659Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.BMC Cancer2017
26957621Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course".J Natl Compr Canc Netw2016
26251290A Multicenter, Open-Label Phase II Clinical Trial of Combined MEK plus EGFR Inhibition for Chemotherapy-Refractory Advanced Pancreatic Adenocarcinoma.Clin Cancer Res2016
27396027The Authors Respond.J Natl Compr Canc Netw2016
  • 1 - 50 of 102

Recommended Authors

Julie M Wilson
Ontario Institute for Cancer Research
Career Start Year 2016
Number of shared co-authors 2
Sahil Seth
The University of Texas MD Anderson Cancer Center
Career Start Year 2014
Number of shared co-authors 36
Dianne Chadwick
University Health Network
Career Start Year 2013
Number of shared co-authors 1
Ashton A Connor
Houston Methodist Hospital
Career Start Year 2012
Number of shared co-authors 1
Anjali V Sheahan
Dana-Farber Cancer Institute
Career Start Year 2012
Number of shared co-authors 1
Robert E Denroche
Ontario Institute for Cancer Research
Career Start Year 2012
Number of shared co-authors 6
Gun Ho Jang
Ontario Institute for Cancer Research
Career Start Year 2011
Number of shared co-authors 2
Eliezer M Van Allen
Dana-Farber Cancer Institute
Career Start Year 2009
Number of shared co-authors 36
Amber L Johns
Garvan Institute of Medical Research and The Kinghorn Cancer Centre
Career Start Year 2009
Number of shared co-authors 6
Jeran K Stratford
Research Triangle Institute (RTI)
Career Start Year 2009
Number of shared co-authors 0
Faiyaz Notta
2Ontario Institute for Cancer Research
Career Start Year 2009
Number of shared co-authors 4
Ashiq Masood
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Career Start Year 2008
Number of shared co-authors 5
Lawrence N Kwong
The University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 26
John Paul Shen
The University of Texas MD Anderson Cancer Center
Career Start Year 2006
Number of shared co-authors 10
Shubham Pant
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 3
Florencia McAllister
The University of Texas MD Anderson Cancer Center
Career Start Year 2005
Number of shared co-authors 4
Jochen K Lennerz
Massachusetts General Hospital/Harvard Medical School
Career Start Year 2004
Number of shared co-authors 11
Kristopher K Frese
Cancer Research UK Manchester Institute, University of Manchester
Career Start Year 2003
Number of shared co-authors 3
Jianhua Zhang
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 35
Tobias Sj??blom
Uppsala University
Career Start Year 1999
Number of shared co-authors 0
Thomas J George
UF Health Cancer Center
Career Start Year 1998
Number of shared co-authors 36
Charles Swanton
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 21
Anthony J Iafrate
Massachusetts General Hospital
Career Start Year 1997
Number of shared co-authors 12
Udo Rudloff
Center for Cancer Research, National Cancer Institute
Career Start Year 1994
Number of shared co-authors 1
Tatsuhiro Shibata
Kurume University School of Medicine
Career Start Year 1993
Number of shared co-authors 9
Paul T Fanta
University of California San Diego Moores Cancer Center
Career Start Year 1992
Number of shared co-authors 6
Nabeel Bardeesy
Massachusetts General Hospital
Career Start Year 1992
Number of shared co-authors 20
Levi A Garraway
Broad Institute of Harvard and MIT
Career Start Year 1991
Number of shared co-authors 27
Nathan Bahary
University of Pittsburgh
Career Start Year 1989
Number of shared co-authors 7
Ming-Sound Tsao
University Health Network, University of Toronto
Career Start Year 1972
Number of shared co-authors 25

Collaborators

Joe W Gray
Oregon Health and Science University
Co-authored papers 16
Paul T Spellman
Oregon Health & Science University Hospital.
Co-authored papers 12
Raymond J Cho
University of California san francisco
Co-authored papers 11
Lakshmi Jakkula
Co-authored papers 8
John Z Sanborn
Co-authored papers 7
Trever G Bivona
University of California san francisco
Co-authored papers 7
James E Korkola
Co-authored papers 7
Gordon B Mills
Knight Cancer Institute, Oregon Health and Sciences University
Co-authored papers 7
Laura M Heiser
Oregon Health Sciences University
Co-authored papers 6
Joshua M Stuart
University of California at Santa Cruz
Co-authored papers 6
Spencer C Behr
University of California san francisco
Co-authored papers 6
Obi L Griffith
Washington University
Co-authored papers 5
Elizabeth Purdom
Co-authored papers 5
David Haussler
Genomics Institute, University of California Santa Cruz
Co-authored papers 5
Matthew Meyerson
Broad Institute
Co-authored papers 4
Ronald M Evans
Co-authored papers 4
John N Weinstein
The University of Texas MD Anderson Cancer Center
Co-authored papers 4
Yiling Lu
Co-authored papers 4
Michael Downes
Howard Hughes Medical Institute, Salk Institute for Biological Studies
Co-authored papers 4
Saurabh Asthana
University of California San Francisco
Co-authored papers 4
Steffen Durinck
Genentech Inc.
Co-authored papers 4
Barry S Taylor
Memorial Sloan Kettering Cancer Center
Co-authored papers 4
Victor Olivas
University of California san francisco
Co-authored papers 4
Valerie M Weaver
University of California san francisco
Co-authored papers 4
Heidi S Feiler
Co-authored papers 4
Theodore C Goldstein
Bakar Computational Health Sciences Institute, University of California san francisco
Co-authored papers 3
Oana M Enache
Co-authored papers 3
Gad Getz
Broad Institute of the Massachusetts Institute of Technology and Harvard
Co-authored papers 3
Christopher C Benz
Buck Institute for Research on Aging
Co-authored papers 3
AmirAli Talasaz
University of California San Diego Moores Cancer Center
Co-authored papers 3
Release 1.2